Effect of rosiglitazone on glucose and non-esterified fatty acid metabolism in Type II diabetic patients

Diabetologia

Volumn 44, Issue 12, 2001, Pages 2210-2219

  Miyazaki, Y ^a   Glass, L ^a   Triplitt, C ^a   Matsuda, M ^a   Cusi, K ^a   Mahankali, A ^a   Mahankali, S ^a   Mandarino, L J ^a   DeFronzo, R A ^a  

^a Mays Cancer Center at UT Health San Antonio   (United States)

Author keywords

Glucose and non esterified fatty acid metabolism; Insulin sensitivity; Rosiglitazone; Type II diabetes mellitus

Indexed keywords

FATTY ACID; GLUCOSE; HEMOGLOBIN A1C; INSULIN; PALMITIC ACID; PLACEBO; ROSIGLITAZONE;

ADULT; AGED; ARTICLE; BODY FAT; BODY WEIGHT; CALORIMETRY; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETES CONTROL; DIET THERAPY; DOUBLE BLIND PROCEDURE; DRUG EFFECT; DRUG MECHANISM; FATTY ACID METABOLISM; FEMALE; GLUCONEOGENESIS; GLUCOSE METABOLISM; HEMOGLOBIN DETERMINATION; HUMAN; INSULIN SENSITIVITY; MALE; METABOLIC CLEARANCE RATE; NON INSULIN DEPENDENT DIABETES MELLITUS; ORAL GLUCOSE TOLERANCE TEST; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL;

ADULT; AGED; BLOOD GLUCOSE; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FATTY ACIDS, NONESTERIFIED; GLUCOSE; GLUCOSE TOLERANCE TEST; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; MIDDLE AGED; OSMOLAR CONCENTRATION; OXIDATION-REDUCTION; REGRESSION ANALYSIS; THIAZOLES; THIAZOLIDINEDIONES;

EID: 0035671770     PISSN: 0012186X     EISSN: None     Source Type: Journal    
DOI: 10.1007/s001250100031     Document Type: Article

References (38)

1. Metabolic effects of new oral hypoglycaemic agent CS-045 in NIDDM subjects
2. Metabolic effects of troglitazone monotherapy in type 2 diabetes mellitus; a randomized, double-blind, placebo-controlled trial
3. Efficacy and metabolic effects of metformin and troglitazone in Type II diabetes mellitus
4. Metabolic effects of troglitazone therapy in type 2 diabetic, obese, and lean normal subjects
5. Troglitazone monotherapy improves glycaemic control in patients with type 2 diabetes mellitus: A randomized, controlled study
6. Troglitazone in combination with sulfonylurea restores glycaemic control in patients with type 2 diabetes
7. PPAR-γ: Adipogenic regulator and thiazolidinedione receptor
8. An antidiabetic thiazolidinedione is a high affinity ligand for peroxisome proliferator-activated receptor γ (PPARγ)
9. Thiazolidinediones produce a conformational change in peroxisomal proliferator-activated receptor-γ: Binding and activation correlate with antidiabetic actions in db/db mice
10. The structure-activity relationship between peroxisome proliferator-activated receptor-γ agonism and the antihyperglycaemic activity of thiazolidinediones
11. Lilly Lecture 1987. The triumvirate: Beta-cell, muscle, liver, A collusion responsible for NIDDM
12. Pioglitazone induces in vivo adipocyte differentiation in obese Zucker fa/fa rats
13. A human peroxisome-proliferator-activated receptor γ is activated by inducers of adipogenesis, including thiazolidinedione drugs
14. Effects of troglitazone on body fat distribution in type 2 diabetic patients
15. Rosiglitazone monotherapy improve glycaemic control in patients with type 2 diabetes: A twelve-week, randomized, placebo-controlled study
16. Long-term effects of troglitazone: Open-label extension studies in type 2 diabetes patients
17. Effect of pioglitazone on glucose metabolism in sulfonylurea-treated diabetic patients with type 2 diabetes
18. Rosiglitazone taken once daily provides effective glycaemic control in patients with type 2 diabetes mellitus
19. Rosiglitazone short-term monotherapy lowers fasting and post-prandial glucose in patients with Type II diabetes
20. PPARγ, the ultimate thrifty gene
21. Total body fat content and fat topography was associated differently with in vivo glucose metabolism in nonobese and obese nondiabetic women
22. Glucose clamp technique: A method for quantifying insulin secretion and resistance
23. Glucose and free fatty acid metabolism in non-insulin dependent mellitus. Evidence for multiple site of insulin resistance
24. Influence of glucose loading and of injected insulin on hepatic glucose output
25. Indirect calorimetry: Methodological and interpretative problems
26. Non-esterified fatty acid metabolism and postprandial lipaemia
27. Relationship between total body water and surface area in normal and obese subjects
28. Insulin sensitivity indices obtained from oral glucose tolerance testing. Comparison with the glycaemiceuglycaemic insulin clamp
29. Pathogenesis of type 2 diabetes: Metabolic and molecular implications for identifying diabetic genes
30. Reciprocal variation in insulin-mediated glucose uptake and pancreatic insulin secretion in women with normal glucose tolerance
31. Fasting hyperglycemia in non-insulin dependent diabetes mellitus: Contribution of excessive hepatic glucose production and impaired tissue glucose uptake
32. Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats
33. Activators of peroxisome proliferator-activated receptor γ have depot-specific effects on human preadipocyte differentiation
34. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in patients with type 2 diabetes mellitus
35. Differences in lipolysis between human subcutaneous and omental adipose tissue
36. Effects of lipid on basal carbohydrate metabolism in normal man
37. The role of TNF alpha and TNF receptors in obesity and insulin resistance
38. The hormone resistin links obesity to diabetes